Terms: = Breast cancer AND CEP17 AND Diagnosis
17 results:
1. Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer.
Peg V; Moline T; Roig M; Saruta Y; Cajal SRY
Diagn Pathol; 2024 Feb; 19(1):32. PubMed ID: 38360676
[TBL] [Abstract] [Full Text] [Related]
2. Predictive markers for pathological complete response (pCR) after neo-adjuvant chemotherapy in HER2-positive breast carcinoma.
Van Bockstal MR; Dano H; Benhaddi N; Dubois D; Vanderveken J; Van Marcke C; Vandermeulen A; Duhoux FP; Vernaeve H; Berlière M; Galant C
Histol Histopathol; 2024 Feb; 39(2):153-164. PubMed ID: 37204204
[TBL] [Abstract] [Full Text] [Related]
3. Establishment and evaluation of digital PCR methods for HER2 copy number variation in breast cancer.
Wang X; Xing D; Liu Z; Zhang Y; Cheng B; Sun S; Wang Q; Dong L
Anal Bioanal Chem; 2023 Feb; 415(4):725-733. PubMed ID: 36571590
[TBL] [Abstract] [Full Text] [Related]
4. Quantitative assessment of HER2 gene amplification of breast cancer using droplet digital PCR.
Otsuji K; Sasaki T; Tanabe M; Seto Y
Pathol Int; 2021 Aug; 71(8):538-547. PubMed ID: 34289525
[TBL] [Abstract] [Full Text] [Related]
5. An Evaluation of Clinicopathological Correlation and Outcome of Human Epidermal Growth Factor Receptor 2 Subgroups Reclassified According to the Latest ASCO/CAP Guideline.
Wang C; Tsang JY; Poon IK; Shao Y; Li JJ; Shea KH; Hlaing T; Wong SI; Tse GM
Clin Breast Cancer; 2022 Jan; 22(1):e114-e122. PubMed ID: 34119429
[TBL] [Abstract] [Full Text] [Related]
6. [Predictive diagnosis in breast cancer - Whats new in 2018?].
Ryška A
Cesk Patol; 2018; 54(1):13-16. PubMed ID: 29631406
[TBL] [Abstract] [Full Text] [Related]
7. Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis.
Wang Y; Tsang JYS; Cui Y; Cui J; Lin Y; Zhao S; Law PTW; Cheung SY; Ng EKO; Tse GMK; Ke Z
Sci Rep; 2017 Jul; 7(1):6752. PubMed ID: 28754904
[TBL] [Abstract] [Full Text] [Related]
8. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract] [Full Text] [Related]
9. Agreement of Different Methods for Tissue Based Detection of HER2 Signal in Invasive breast cancer.
Thakral G; Wey A; Rahman M; Fang R; Lum C
Pathol Oncol Res; 2017 Jan; 23(1):79-84. PubMed ID: 27417320
[TBL] [Abstract] [Full Text] [Related]
10. HER2 gene copy number and breast cancer-specific survival.
Biserni GB; Engstrøm MJ; Bofin AM
Histopathology; 2016 Nov; 69(5):871-879. PubMed ID: 27271096
[TBL] [Abstract] [Full Text] [Related]
11. The relation between percentage of immunostained cells and amplification status in breast cancers with equivocal result for Her2 immunohistochemistry.
Onguru O; Zhang PJ
Pathol Res Pract; 2016 May; 212(5):381-4. PubMed ID: 26872536
[TBL] [Abstract] [Full Text] [Related]
12. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer.
Horii R; Matsuura M; Iwase T; Ito Y; Akiyama F
Breast Cancer; 2014 Sep; 21(5):598-604. PubMed ID: 23307494
[TBL] [Abstract] [Full Text] [Related]
14. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
[TBL] [Abstract] [Full Text] [Related]
15. [Intratumoral heterogeneity of HER2 status in breast carcinoma].
Ohlschlegel C; Zahel K; Kradolfer D; Hell M; Jochum W
Pathologe; 2010 Oct; 31 Suppl 2():292-5. PubMed ID: 20652266
[TBL] [Abstract] [Full Text] [Related]
16. Standardization of HER2 testing: results of an international proficiency-testing ring study.
Dowsett M; Hanna WM; Kockx M; Penault-Llorca F; Rüschoff J; Gutjahr T; Habben K; van de Vijver MJ
Mod Pathol; 2007 May; 20(5):584-91. PubMed ID: 17396141
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry.
Ogura H; Akiyama F; Kasumi F; Kazui T; Sakamoto G
Breast Cancer; 2003; 10(3):234-40. PubMed ID: 12955036
[TBL] [Abstract] [Full Text] [Related]
